Technical Analysis for NTLA - Intellia Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 130.49 | -0.97% | -1.28 |
Earnings due: Nov 3
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Historical NTLA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Multiple of Ten Bullish | Other | -0.97% | |
| Wide Bands | Range Expansion | -0.97% | |
| Wide Bands | Range Expansion | 4.10% | |
| Stochastic Reached Oversold | Weakness | 1.88% | |
| Multiple of Ten Bearish | Other | 1.88% | |
| Wide Bands | Range Expansion | 1.88% | |
| Oversold Stochastic | Weakness | 1.88% | |
| New Downtrend | Bearish | 3.62% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 3.62% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Down 1% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Up 2% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/03/2021
Intellia Therapeutics, Inc. Description
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Genetics Molecular Biology Hepatitis B Precision Medicine Metabolism Amyloid Liver Disease Hematopoietic Stem Cell Hepatitis B Virus Amyloidosis Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Liver Diseases Antitrypsin Deficiency Cell Product CRISPR Genome Editing Inborn Errors Of Metabolism Transthyretin Cas9 Transthyretin Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 202.73 |
| 52 Week Low | 22.17 |
| Average Volume | 873,081 |
| 200-Day Moving Average | 100.82 |
| 50-Day Moving Average | 149.52 |
| 20-Day Moving Average | 136.28 |
| 10-Day Moving Average | 128.33 |
| Average True Range | 8.53 |
| ADX | 26.16 |
| +DI | 16.42 |
| -DI | 25.56 |
| Chandelier Exit (Long, 3 ATRs) | 133.26 |
| Chandelier Exit (Short, 3 ATRs) | 143.58 |
| Upper Bollinger Bands | 155.69 |
| Lower Bollinger Band | 116.88 |
| Percent B (%b) | 0.35 |
| BandWidth | 28.48 |
| MACD Line | -6.46 |
| MACD Signal Line | -6.39 |
| MACD Histogram | -0.073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 138.77 | ||||
| Resistance 3 (R3) | 139.53 | 137.52 | 137.39 | ||
| Resistance 2 (R2) | 137.52 | 135.41 | 137.15 | 136.93 | |
| Resistance 1 (R1) | 134.01 | 134.11 | 133.01 | 133.25 | 136.47 |
| Pivot Point | 132.00 | 132.00 | 131.50 | 131.63 | 132.00 |
| Support 1 (S1) | 128.49 | 129.89 | 127.49 | 127.73 | 124.51 |
| Support 2 (S2) | 126.48 | 128.59 | 126.11 | 124.05 | |
| Support 3 (S3) | 122.97 | 126.48 | 123.59 | ||
| Support 4 (S4) | 122.21 |
